Jilin Aodong released its 2026 interim report. First-half net profit attributable to the parent was 2.05 billion yuan, up 59.96% year on year. Operating revenue was 1.031 billion yuan, down 8.5% year on year. Net profit attributable to the parent excluding non-recurring items was 2.228 billion yuan, up 90.9% year on year. Net operating cash flow was 194 million yuan, up 26.6% year on year. Earnings per share were 1.7486 yuan. In the second quarter, operating revenue was 517 million yuan, up 2.6% year on year. Net profit attributable to the parent was 1.18 billion yuan, up 54.8% year on year. Net profit attributable to the parent excluding non-recurring items was 1.36 billion yuan, up 100.2% year on year. As of the end of the second quarter, total assets were 36.049 billion yuan, up 4.7% from the end of the previous year. Net assets attributable to the parent were 31.989 billion yuan, up 4.3% from the end of the previous year. The company said its main business has not undergone major changes. It continues to focus on the research, development, manufacturing and sales of traditional Chinese medicines and chemical drugs, while advancing intelligent manufacturing and omni-channel marketing.
Jilin Aodong Pharmaceutical Group Co LtdFirst-half net profit attributable to parent up 59.96% year on year, with non-recurring net profit up 90.9%.
